Sino Biopharmaceutical Limited (HKG: 1177)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.240
+0.020 (0.62%)
Dec 24, 2024, 12:08 PM HKT

Sino Biopharmaceutical Statistics

Total Valuation

Sino Biopharmaceutical has a market cap or net worth of HKD 58.80 billion. The enterprise value is 65.01 billion.

Market Cap 58.80B
Enterprise Value 65.01B

Important Dates

The next estimated earnings date is Thursday, March 27, 2025.

Earnings Date Mar 27, 2025
Ex-Dividend Date Sep 10, 2024

Share Statistics

Sino Biopharmaceutical has 18.21 billion shares outstanding. The number of shares has decreased by -2.25% in one year.

Current Share Class n/a
Shares Outstanding 18.21B
Shares Change (YoY) -2.25%
Shares Change (QoQ) n/a
Owned by Insiders (%) 49.69%
Owned by Institutions (%) 17.38%
Float 9.16B

Valuation Ratios

The trailing PE ratio is 25.89 and the forward PE ratio is 17.72. Sino Biopharmaceutical's PEG ratio is 1.26.

PE Ratio 25.89
Forward PE 17.72
PS Ratio 2.00
PB Ratio 1.67
P/TBV Ratio 1.84
P/FCF Ratio 9.51
P/OCF Ratio n/a
PEG Ratio 1.26
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.52, with an EV/FCF ratio of 10.52.

EV / Earnings 14.79
EV / Sales 2.18
EV / EBITDA 9.52
EV / EBIT 11.06
EV / FCF 10.52

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.23.

Current Ratio 1.15
Quick Ratio 0.94
Debt / Equity 0.23
Debt / EBITDA 1.43
Debt / FCF 1.68
Interest Coverage 16.51

Financial Efficiency

Return on equity (ROE) is 12.87% and return on invested capital (ROIC) is 7.35%.

Return on Equity (ROE) 12.87%
Return on Assets (ROA) 5.54%
Return on Capital (ROIC) 7.35%
Revenue Per Employee 1.22M
Profits Per Employee 179,852
Employee Count 25,806
Asset Turnover 0.42
Inventory Turnover 2.72

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +2.21% in the last 52 weeks. The beta is 0.72, so Sino Biopharmaceutical's price volatility has been lower than the market average.

Beta (5Y) 0.72
52-Week Price Change +2.21%
50-Day Moving Average 3.39
200-Day Moving Average 3.10
Relative Strength Index (RSI) 44.52
Average Volume (20 Days) 46,430,835

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Sino Biopharmaceutical had revenue of HKD 29.86 billion and earned 4.40 billion in profits. Earnings per share was 0.24.

Revenue 29.86B
Gross Profit 24.24B
Operating Income 6.31B
Pretax Income 6.41B
Net Income 4.40B
EBITDA 7.20B
EBIT 6.31B
Earnings Per Share (EPS) 0.24
Full Income Statement

Balance Sheet

The company has 14.16 billion in cash and 10.40 billion in debt, giving a net cash position of 3.76 billion or 0.21 per share.

Cash & Cash Equivalents 14.16B
Total Debt 10.40B
Net Cash 3.76B
Net Cash Per Share 0.21
Equity (Book Value) 45.26B
Book Value Per Share 1.94
Working Capital 3.52B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.96 billion and capital expenditures -775.15 million, giving a free cash flow of 6.18 billion.

Operating Cash Flow 6.96B
Capital Expenditures -775.15M
Free Cash Flow 6.18B
FCF Per Share 0.34
Full Cash Flow Statement

Margins

Gross margin is 81.16%, with operating and profit margins of 21.12% and 14.72%.

Gross Margin 81.16%
Operating Margin 21.12%
Pretax Margin 21.48%
Profit Margin 14.72%
EBITDA Margin 24.11%
EBIT Margin 21.12%
FCF Margin 20.70%

Dividends & Yields

This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.85%.

Dividend Per Share 0.06
Dividend Yield 1.85%
Dividend Growth (YoY) -25.00%
Years of Dividend Growth n/a
Payout Ratio 15.47%
Buyback Yield 2.25%
Shareholder Yield 4.11%
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Stock Splits

The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.

Last Split Date Jul 20, 2020
Split Type Forward
Split Ratio 1.5

Scores

Sino Biopharmaceutical has an Altman Z-Score of 2.71. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.71
Piotroski F-Score n/a